Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum

Yan‐Shan Dai(Central South University), Vibha Jawa(Bristol-Myers Squibb (Germany)), Carol Gleason(Bristol-Myers Squibb (United States)), Johanna Mora(Bristol-Myers Squibb (United States)), Huijin Dong(Bristol-Myers Squibb (United States)), Alexander Kozhich(Institute of Neuroimmunology of the Slovak Academy of Sciences), Nanda Balasubramanian(Bristol-Myers Squibb (United States)), Sekhar Surapaneni(Bristol-Myers Squibb (United States)), Gerry Kolaitis(Bristol-Myers Squibb (United States))
The AAPS Journal
April 3, 2023
10.1208/s12248-023-00805-6
Cited by 12

Related Papers

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)
|Bioanalysis|2019|94
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57